Healthcare Industry News: GSK
News Release - February 12, 2007
King Pharmaceuticals Appoints Eric G. Carter as Chief Science OfficerBRISTOL, Tenn.--(HSMN NewsFeed)--King Pharmaceuticals, Inc. (NYSE: KG ) announced today the appointment of Eric G. Carter as the Company's Chief Science Officer. Dr. Carter will oversee all of King's research and development, regulatory and medical affairs activities.
Brian A. Markison, President and Chief Executive Officer of King, stated, "We are extremely pleased to have Dr. Carter join our executive management team as our Chief Science Officer." Mr. Markison continued, "Dr. Carter's impressive academic and scientific background and established leadership in our industry make him an ideal choice to lead King's research and development organization. With his experience, he brings a solid understanding of the commercial facets of product development and life cycle management. We look forward to his contributions to our Company as we continue to build value for our shareholders."
Dr. Carter joins King with more than 25 years of clinical development and medical affairs experience, including 10 years of senior management experience within the pharmaceutical industry. Most recently, Dr. Carter served as Vice President and Global Head, Clinical Development and Medical Affairs, Gastroenterology, R&D for GlaxoSmithKline ("GSK"). His earlier experience at GSK includes North American responsibility for Gastroenterology and for Emerging therapeutic areas. Prior to GSK, Dr. Carter was employed by Pharmacia & Upjohn as Vice President, Medical and Clinical Affairs, in the United States and Sweden.
In addition to his industry experience, Dr. Carter has a distinguished background in academics. He has served as a Clinical Associate Professor at the University of North Carolina for the Division of Digestive Diseases and Nutrition, School of Medicine, and earlier in his career, Dr. Carter held academic positions with the University of California, where he was responsible for establishing and directing many research programs.
After earning a bachelor's degree in Biochemistry from the University of London, Dr. Carter received his M.D. from the University of Miami and Ph.D. from the University of Cambridge. He obtained board certification from the American Board of Internal Medicine, Gastroenterology and Clinical Nutrition and has authored or co-authored more than 50 scientific publications. Dr. Carter is a member of the American College of Physicians, the American Gastroenterology Association and the American Academy of Pharmaceutical Physicians.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
Source: King Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.